Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Asimov logo — Intelligent design of living systems

Asimov

Intelligent design of living systems

Founded 2017 United States Boston, United States 119 employees Series B Total: $204.70M AI, Biotechnology +1

General Information

Company Name Asimov
Founded Year 2017
Location United States Boston, United States +1
Founders / Decision Makers
Team member Team member
Employees 119
Industries AI, Biotechnology, Health and Wellness
Funding Stage Series B
Social

Get notified when Asimov moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Asimov is demonstrating strong momentum through significant product innovation and market traction. Recent highlights include a major customer win with Amgen, showcasing an 11-fold increase in stable pool titer, alongside the launch of a stable AAV system and substantial enhancements to their CHO Edge System, driving up mAb titers by 25%. These developments underscore the company's continuous advancements in biomanufacturing efficiency and its expanding role in the synthetic biology landscape.

Signal Types
Customer Acquisition Product Launch Product Enhancement Product Performance Partnership
Strategic Labels
Biologics Platform Growth Synthetic Biology Innovation Market Expansion
Next Move: Commercialization
·
Impact: 9/10
·
Ideal For: Growth Stage Biotech VCs — Synthetic Biology Tools

About Asimov

Asimov is at the forefront of bioengineering, propelling the AI, Biotechnology, and Health and Wellness industries with its innovative approach to cellular programming. Founded in 2017, the company harnesses the synergies of mammalian synthetic biology, computer-aided design, and machine learning. This unique blend aims to revolutionize the design and manufacturing processes for biologics and gene therapies.

Headquartered in the United States, Asimov recently secured a substantial $175.00M Series B investment on 01 January 2023. This financial milestone was backed by a cohort of notable investors, including CPP Investments, Pillar, Casdin Capital, KdT Ventures, Andreessen Horowitz/a16z, Horizons Ventures, and Fidelity Investments. Such robust support from reputable investors underscores the company's potential and the confidence stakeholders have in its vision.

Taxonomy: Intelligent Design, Living Systems, Synthetic Biology, Mammalian Biology, Computer-Aided Design, Biologics Manufacturing, Gene Therapies, Cell Programming, Biotech Innovation, Bioengineering, Life Sciences, Cell Engineering

Services & Products

end-to-end genetic design platform
cell line development
gene and RNA therapy production
biological tools and computational models
lab-in-the-loop platform
design and manufacturing integration

Target Customers

biotech companies pharmaceutical companies synthetic biologists research institutions healthcare innovators biotherapeutics developers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Jan 2023
Series A •••••• 1
Investor
01 Dec 2019
Seed •••••• 1
Investor
01 Dec 2017
Spinout •••••• 2 •••• •••• 01 Jan 2017

Asimov Alternatives & Competitors

View All Alternatives
Asimov vs
Cellyrix
Cellyrix

Revolutionizing cancer treatment by modulating aggressive tumor cell behavior.

Asimov vs
Kernel
Kernel

Intelligent design of living systems.

Asimov vs
Adaptyv
Adaptyv Switzerland

The cloud lab for protein designers

Series A
36 employees
Biotechnology, Pharmaceutical
Compare Asimov vs Adaptyv
Also compare with: Asimov vs Cairn Biosciences Cairn Biosciences Asimov vs RemedyBio RemedyBio View all alternatives

FAQ About Asimov

Intelligent design of living systems
Asimov was founded in 2017.
Asimov is headquartered in Boston, United States.
Asimov operates in the following industries: AI, Biotechnology, Health and Wellness.
Asimov has approximately 119 employees.
Asimov has completed 4 funding rounds, raising a total of $204.70M. The latest funding stage is Series B.
Asimov offers: end-to-end genetic design platform, cell line development, gene and RNA therapy production, biological tools and computational models, lab-in-the-loop platform, design and manufacturing integration.
Top alternatives and competitors to Asimov include Cellyrix, Kernel, Adaptyv, Trailhead Biosystems, Cairn Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Asimov and Cellyrix are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Asimov and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy